Search results
Results From The WOW.Com Content Network
VolunteerMatch is free to use by individuals. [4] Nonprofit organizations may elect a free basic account or opt for more robust recruiting tools by becoming VolunteerMatch Members. Regional and national organizations with multiple chapters can elect for Group Membership which includes a bundle of enterprise tools for regional and national ...
Two main types of corporate volunteer grants are: 1. Individual volunteer grants – These are small grants of around $250–$750 which are given to nonprofits to recognize an employee's volunteer commitment upon reaching a certain number of volunteer hours in a year (usually 10–50 hours).
1. Sign in to your My Account page. 2. Click My Wallet. 3. Click Payment Methods. 4. Click Add Credit or Debit Card. 5. Enter the required info. 6. Click Submit.
2014 – Merck KGaA announced that it would purchase Sigma-Aldrich for approx. $17 billion (€13.1 billion). [16] [17] November 3, 2014 – Sigma-Aldrich filed a definitive proxy statement with the U.S. Securities and Exchange Commission to hold a special investors meeting regarding approval for the sale to Merck KGaA. [18]
This includes your AOL username and email account accessible at mail.aol.com, AOL security services protecting against spam and viruses within your AOL mail account, your AOL Address Book for contacts, as well as AOL.com, AOL Video and AOL Search. View all of your free benefits on your MyBenefits page. Rejoin to an AOL plan
The PSD contained two main sections: The "market rules" described which type of organisations could provide payment services. Next to credit institutions (i.e. banks) and certain authorities (e.g. central banks, government bodies), the PSD mentioned electronic money institutions (EMI), created by the E-Money Directive in 2000, and created the new category of "payment institutions" (PI) with ...
Created Date: 8/30/2012 4:52:52 PM
On Monday, Ligand Pharmaceuticals (NAS: LGND) confirmed that Merck (NYS: MRK) will pay it a $2 million milestone payment, as the latter begins phase 2b/3 clinical trials of a new cancer drug.